Edition:
United Kingdom

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

33.29USD
17 Jun 2019
Change (% chg)

$1.57 (+4.95%)
Prev Close
$31.72
Open
$31.82
Day's High
$33.65
Day's Low
$31.74
Volume
198,727
Avg. Vol
189,641
52-wk High
$74.75
52-wk Low
$31.01

Latest Key Developments (Source: Significant Developments)

Aerie Pharmaceuticals Announces FDA Approval Of Rocklatan
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF ROCKLATAN(NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.AERIE PHARMACEUTICALS INC - COMPANY PLANS TO LAUNCH ROCKLATAN IN UNITED STATES IN Q2 OF 2019.  Full Article

Aerie Pharma Q4 GAAP Loss Per Share $1.14
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS, PROVIDES 2019 CASH BURN GUIDANCE AND BUSINESS UPDATE.Q4 ADJUSTED LOSS PER SHARE $0.92.Q4 GAAP LOSS PER SHARE $1.14.Q4 EARNINGS PER SHARE ESTIMATE $-0.87 -- REFINITIV IBES DATA.AERIE PHARMACEUTICALS - GUIDANCE FOR 2019 FULL-YEAR CASH BURN IS CONSISTENT WITH FULL-YEAR 2018 ACTUAL RESULTS, IN RANGE OF $210 MILLION TO $220 MILLION.ENTERING 2019 VERY WELL FINANCED, WITH OVER $300 MILLION IN AVAILABLE LIQUIDITY.Q4 REVENUE $14.5 MILLION.  Full Article

Aerie Pharmaceuticals Files Supplement Related To Offering Of 329,124 Shares By Selling Stockholders - SEC Filing
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS INC FILES PROSPECTUS SUPPLEMENT RELATES TO OFFERING OF 329,124 SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Aerie Pharmaceuticals Q2 GAAP Loss Per Share $1.40
Wednesday, 8 Aug 2018 

Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 ADJUSTED LOSS PER SHARE $1.14.Q2 GAAP LOSS PER SHARE $1.40.Q2 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.AERIE PHARMACEUTICALS - $286.1 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30.AERIE PHARMACEUTICALS - REITERATED 2018 RHOPRESSA NET REVENUES, TOTAL 2018 CASH BURN GUIDANCE.  Full Article

Aerie Pharmaceuticals And DSM Biomedical Expand Collaboration Agreement
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS, INC. AND DSM BIOMEDICAL, INC. EXPAND COLLABORATION AGREEMENT FOCUSED ON NOVEL DRUG DELIVERY TECHNOLOGY IN OPHTHALMOLOGY.AERIE PHARMACEUTICALS - PAID $6.0 MILLION TO DSM UPON SIGNING OF EXPANDED AGREEMENT, WITH AN ADDITIONAL $9.0 MILLION PAYABLE TO DSM THROUGH END OF 2020.AERIE PHARMACEUTICALS - TO HAVE EXCLUSIVE LICENSE FOR OPHTHALMIC INDICATIONS TO DSM'S POLYESTERAMIDE POLYMER TECHNOLOGY FOR UNLIMITED NUMBER OF COMPOUNDS.AERIE PHARMACEUTICALS INC - AERIE AND DSM WILL CONTINUE COLLABORATIVE RESEARCH ACTIVITIES THROUGH END OF 2020.AERIE PHARMACEUTICALS - WILL GAIN ACCESS TO DSM'S PRECLINICAL STAGE LATANOPROST IMPLANT WITH POTENTIAL FOR INITIAL CLINICAL STUDIES IN GLAUCOMA PATIENTS IN 2019.  Full Article

Aerie Pharmaceuticals Announces Deerfield’S Conversion Of Convertible Notes Into Aerie Common Stock
Monday, 23 Jul 2018 

July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES DEERFIELD’S CONVERSION OF CONVERTIBLE NOTES INTO AERIE COMMON STOCK AND ESTABLISHMENT OF AN UNDRAWN $100M CREDIT FACILITY WITH DEERFIELD.ENTERED INTO A $100 MILLION SENIOR SECURED DELAYED DRAW TERM LOAN FACILITY WITH AFFILIATES OF DEERFIELD.CREDIT FACILITY MATURES ON JULY 23, 2024.  Full Article

Aerie Pharmaceuticals Announces Early Notification Of FDA Acceptance Of NDA Submission For Roclatan
Monday, 23 Jul 2018 

July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES EARLY NOTIFICATION OF FDA ACCEPTANCE OF NDA SUBMISSION FOR ROCLATAN™ (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% WITH PDUFA DATE SET FOR MARCH 14, 2019.AERIE - "DAY 74" NOTIFICATION INDICATED THAT FDA HAS NOT IDENTIFIED ANY POTENTIAL REVIEW ISSUES.AERIE PHARMACEUTICALS INC - "DAY 74" NOTIFICATION DID NOT MENTION NEED FOR AN ADVISORY COMMITTEE.  Full Article

Aerie Pharmaceuticals Announces Early Notification Of FDA Acceptance Of NDA Submission For Roclatan
Monday, 23 Jul 2018 

July 23 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES EARLY NOTIFICATION OF FDA ACCEPTANCE OF NDA SUBMISSION FOR ROCLATAN™ (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005% WITH PDUFA DATE SET FOR MARCH 14, 2019.AERIE - "DAY 74" NOTIFICATION INDICATED THAT FDA HAS NOT IDENTIFIED ANY POTENTIAL REVIEW ISSUES.AERIE PHARMACEUTICALS INC - "DAY 74" NOTIFICATION DID NOT MENTION NEED FOR AN ADVISORY COMMITTEE.  Full Article

Aerie Pharmaceuticals Submits NDA To U.S. FDA For Roclatantm
Tuesday, 15 May 2018 

May 15 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ROCLATANTM (NETARSUDIL/LATANOPROST OPHTHALMIC SOLUTION) 0.02%/0.005%.AERIE PHARMACEUTICALS - EXPECTED FDA REVIEW PERIOD FOR ROCLATAN NDA IS TEN MONTHS.AERIE PHARMACEUTICALS INC - NDA SUBMITTED AS A 505(B)(2) WITH AN EXPECTED TEN-MONTH FDA REVIEW.  Full Article

Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%
Monday, 30 Apr 2018 

April 30 (Reuters) - Aerie Pharmaceuticals Inc ::AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%.AERIE - FORMULARY CONTRACTS FOR COMMERCIAL INSURANCE COVERAGE IN 2018, MEDICARE PART D PROGRAM COVERAGE BEGINNING 2019 IN FINAL STAGES OF EXECUTION.  Full Article